These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 4872692)
61. [On the use of the chlorpromazine-promethazine- phenobarbital association in psychiatry. Clinical study of 60 cases]. D'Errico A; Morello G; Turchiaro G Minerva Med; 1966 Jan; 57(8):270-4. PubMed ID: 5908333 [No Abstract] [Full Text] [Related]
62. [Therapeutic prevention of climatic disorders]. MERCK HL; UNGEHEUER H Munch Med Wochenschr; 1957 Feb; 99(7):212-4. PubMed ID: 13407681 [No Abstract] [Full Text] [Related]
63. Reserpine added to neuroleptic-tricyclic in refractory schizophrenics. Bacher N; Lewis H J Clin Psychiatry; 1981 Aug; 42(8):326. PubMed ID: 7019202 [No Abstract] [Full Text] [Related]
64. [Neuroplegic medications and cures in psychiatry: preliminary trials with reserpine; comparison with the effects of chlorpromazine]. DELAY J; DENIKER P; TARDIEU Y; LEMPERIERE T Presse Med (1893); 1955 May; 63(32):663-5. PubMed ID: 14395087 [No Abstract] [Full Text] [Related]
65. An appraisal of the continuing practice of prescribing tranquillizing drugs for long-stay psychiatric patients. Hughes JS; Little JC Br J Psychiatry; 1967 Aug; 113(501):867-73. PubMed ID: 4860437 [No Abstract] [Full Text] [Related]
66. [Examination of vegetative regulation under the influence of depressants]. AMELUNG W; LOTZ R Medizinische; 1956 Oct; 24(42):1507-9. PubMed ID: 13377976 [No Abstract] [Full Text] [Related]
67. Treatment of acute mental disorders with an adrenal steroid. Loranger AW Br J Psychiatry; 1968 Jul; 114(512):843-4. PubMed ID: 4874165 [No Abstract] [Full Text] [Related]
68. [Report on the use of Akineton in reserpineinduced Parkinsonoid states]. BROSCH H Med Welt; 1963 May; 18():1035-7. PubMed ID: 14015830 [No Abstract] [Full Text] [Related]
69. Annual NCDEU meeting (1985): New Clinical Drug Evaulation Unit. Abridged proceedings. Psychopharmacol Bull; 1986; 22(1):1-337. PubMed ID: 3726053 [No Abstract] [Full Text] [Related]
70. [The present status of and perspectives in psychopharmacology]. Vinar O Act Nerv Super (Praha); 1968 Oct; 10(3):347-54. PubMed ID: 4883243 [No Abstract] [Full Text] [Related]
71. [Treatment of parkinsonism with the Bulgarian preparations INHA-17 and bellazon]. Stoliarova LG Zh Nevropatol Psikhiatr Im S S Korsakova; 1966; 66(5):698-703. PubMed ID: 4873628 [No Abstract] [Full Text] [Related]
72. [Bulgarian antiparkinson preparations with a new mechanism of action]. Ganev G; Karamalakov L; Tsekova M Zh Nevropatol Psikhiatr Im S S Korsakova; 1966; 66(12):1864-9. PubMed ID: 6000490 [No Abstract] [Full Text] [Related]
73. Lack of indication for use of antiparkinson medication. A follow-up study. Pecknold JC; Ananth JV; Ban TA; Lehmann HE Dis Nerv Syst; 1971 Aug; 32(8):538-41. PubMed ID: 5094160 [No Abstract] [Full Text] [Related]
74. [Psychomotility, extrapyramidal syndrome and mode of action of neuroleptic therapies; chlorpromazine, reserpine and prochlorperazine]. FREYHAN FA Nervenarzt; 1957 Nov; 28(11):504-9. PubMed ID: 13517440 [No Abstract] [Full Text] [Related]
75. [Prophylaxis of neuroleptic parkonsonism with the Bulgarian drug INKhA-17 (Paabainkh) and bellazon]. Ganev G; Karamalakov L; Milenkov K; Ianachkova M; Sakhatchieva L; Kiuchukova P; Roĭlev I; Naumov I; Cheshmedzhiev P; Dochkov Zh Zh Nevropatol Psikhiatr Im S S Korsakova; 1968; 68(3):365-8. PubMed ID: 4872692 [No Abstract] [Full Text] [Related]